Ascendis Pharma A/S Stock Forecast
NASDAQ: ASNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ASND analyst consensus
Consensus (20 analysts)
strong_buy
Avg. price target
$305.84+33.90%
- Strong buy 5
- Buy 15
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering Ascendis Pharma A/S (2026-10-07), 20 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $305.84, with a high estimate of $349.56 and a low estimate of $261.99. The average target implies upside of 33.9% from the current price of $228.41.
The spread between the highest and lowest targets is 33.4%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ASND.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 25% |
| Buy | 15 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $261.99 | +14.70% |
| Average target | $305.84 | +33.90% |
| High target | $349.56 | +53.04% |